Cargando…

Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study

In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC). Epidemiological studies, however, have been equivocal. We undertook this study to assess whether metformin prevents CRC in individuals with type II diabetes. We performed a nested case–control study restricted to D...

Descripción completa

Detalles Bibliográficos
Autores principales: Cardel, Majken, Jensen, Sara M, Pottegård, Anton, Jørgensen, Trine L, Hallas, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302696/
https://www.ncbi.nlm.nih.gov/pubmed/25091592
http://dx.doi.org/10.1002/cam4.306
_version_ 1782353856624066560
author Cardel, Majken
Jensen, Sara M
Pottegård, Anton
Jørgensen, Trine L
Hallas, Jesper
author_facet Cardel, Majken
Jensen, Sara M
Pottegård, Anton
Jørgensen, Trine L
Hallas, Jesper
author_sort Cardel, Majken
collection PubMed
description In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC). Epidemiological studies, however, have been equivocal. We undertook this study to assess whether metformin prevents CRC in individuals with type II diabetes. We performed a nested case–control study restricted to Danish citizens with type II diabetes. Data were collected from four Danish nationwide registries. Cases were type II diabetics with a primary CRC between 2000 and 2009, and controls were sampled among subjects with type II diabetes. Long-term exposure to metformin was defined by the redeeming of prescriptions for a cumulative dose of 2000 g within 5 years prior to the index date. To control for potential confounders, we used unconditional logistic regression. We generated adjusted odds ratios (OR) for the association between metformin and CRC and performed subanalyses for selected subgroups and for the dose–response relation. We identified 2088 cases and 9060 controls during the study period. The association between long-term metformin use and CRC gave an adjusted OR at 0.83 (95% CI 0.68–1.00). A protective effect on CRC with long-term use of metformin was only evident for women (OR 0.66 vs. 0.99 for men). There was a significant dose–response association of metformin use >250 defined daily dose (DDD) and for the duration of metformin use >1 year. We found an indication of a protective effect of long-term metformin use against CRC in type II diabetics, although this effect was only seen in women.
format Online
Article
Text
id pubmed-4302696
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43026962015-01-22 Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study Cardel, Majken Jensen, Sara M Pottegård, Anton Jørgensen, Trine L Hallas, Jesper Cancer Med Cancer Prevention In vitro and animal studies indicate that metformin prevents colorectal cancer (CRC). Epidemiological studies, however, have been equivocal. We undertook this study to assess whether metformin prevents CRC in individuals with type II diabetes. We performed a nested case–control study restricted to Danish citizens with type II diabetes. Data were collected from four Danish nationwide registries. Cases were type II diabetics with a primary CRC between 2000 and 2009, and controls were sampled among subjects with type II diabetes. Long-term exposure to metformin was defined by the redeeming of prescriptions for a cumulative dose of 2000 g within 5 years prior to the index date. To control for potential confounders, we used unconditional logistic regression. We generated adjusted odds ratios (OR) for the association between metformin and CRC and performed subanalyses for selected subgroups and for the dose–response relation. We identified 2088 cases and 9060 controls during the study period. The association between long-term metformin use and CRC gave an adjusted OR at 0.83 (95% CI 0.68–1.00). A protective effect on CRC with long-term use of metformin was only evident for women (OR 0.66 vs. 0.99 for men). There was a significant dose–response association of metformin use >250 defined daily dose (DDD) and for the duration of metformin use >1 year. We found an indication of a protective effect of long-term metformin use against CRC in type II diabetics, although this effect was only seen in women. Blackwell Publishing Ltd 2014-10 2014-08-05 /pmc/articles/PMC4302696/ /pubmed/25091592 http://dx.doi.org/10.1002/cam4.306 Text en © 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Cardel, Majken
Jensen, Sara M
Pottegård, Anton
Jørgensen, Trine L
Hallas, Jesper
Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title_full Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title_fullStr Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title_full_unstemmed Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title_short Long-term use of metformin and colorectal cancer risk in type II diabetics: a population-based case–control study
title_sort long-term use of metformin and colorectal cancer risk in type ii diabetics: a population-based case–control study
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302696/
https://www.ncbi.nlm.nih.gov/pubmed/25091592
http://dx.doi.org/10.1002/cam4.306
work_keys_str_mv AT cardelmajken longtermuseofmetforminandcolorectalcancerriskintypeiidiabeticsapopulationbasedcasecontrolstudy
AT jensensaram longtermuseofmetforminandcolorectalcancerriskintypeiidiabeticsapopulationbasedcasecontrolstudy
AT pottegardanton longtermuseofmetforminandcolorectalcancerriskintypeiidiabeticsapopulationbasedcasecontrolstudy
AT jørgensentrinel longtermuseofmetforminandcolorectalcancerriskintypeiidiabeticsapopulationbasedcasecontrolstudy
AT hallasjesper longtermuseofmetforminandcolorectalcancerriskintypeiidiabeticsapopulationbasedcasecontrolstudy